First-in-human testing for DF-003, second compound from the IDInVivo and MedChem5 platforms to enter clinical trials
Guilford, Conn. and Shanghai, September 19, 2023–(BUSINESS WIRE)– Drug Pharm, a clinical-stage biopharmaceutical company, today announced that the first subject in the Phase 1 clinical trial (NCT05997641) evaluating DF-003 in healthy volunteers has been dosed. DF-003, discovered through Drug Pharm’s IDInVivo and MedChem5 platform technologies, is an investigational small molecule drug that inhibits alpha-kinase 1 (ALPK1), one of the inflammatory pathways underlying disease pathology in cardio-renal diseases. A major goal is to regulate. Gain-of-function mutations in ALPK1 also cause a rare genetic disease, Rosacea syndrome, which causes blindness.
“We are excited to see our technology lead to this study leading to a first-in-class drug, DF-003,” said Dr. Tony Xu, Ph.D., co-founder and Chief Operating Officer. Of drug farm. DF-003 is a potent, highly selective, orally bioavailable ALPK1 inhibitor with preclinical efficacy in cardio-renal and ROSAH disease animal models.
“The Phase 1 study will evaluate DF-003 with single and multiple ascending doses in healthy volunteers that will inform dose selection for Phase 2 programs. We look forward to completing the Phase 1 study and developing a new drug for patients with heart disease and kidney disease, and Rosacea syndrome,” said Dr. Jason Yogaratnam, MB.BCh, MRCSEd, Ph.D., MBA, Chief Medical Officer of Drug Pharm.
About drug farm
The drug pharm is a private biotechnology company developing innovative treatments targeting innate immunity for hepatitis B, heart and kidney diseases and Rosacea (retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis and headache) syndrome. The drug pharm’s unique IDInVivo platform combines key technologies in genetics and AI to discover new treatments. IDInVivo technology allows direct assessment of gene targets in live animals with intact immune systems. Using the IDInVivo platform, the drug farm has identified new innate immune pathways and targets and is now rapidly advancing multiple first-in-class drug candidates into clinical development. For more information please visit: www.drug-farm.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20230919496106/en/
United States of america:
Henry Lichtenstein, Ph.D.
chief executive officer
Tony Xu, Ph.D.
Co-Founder and Chief Operating Officer